{"id":30812,"date":"2022-06-27T14:03:29","date_gmt":"2022-06-27T12:03:29","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=30812"},"modified":"2022-06-27T14:03:29","modified_gmt":"2022-06-27T12:03:29","slug":"mavacamten-bei-der-obstruktiven-form-der-hypertrophen-kardiomyopathie-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/mavacamten-bei-der-obstruktiven-form-der-hypertrophen-kardiomyopathie-cme","title":{"rendered":"Mavacamten bei der obstruktiven Form der hypertrophen Kardiomyopathie [CME]"},"content":{"rendered":"<p>Im April 2022 erteilte die US-amerikanische Food and Drug Administration (FDA) die Marktzulassung f\u00fcr Mavacamten (Camzyos\u00ae; Bristol Myers Squibb) zur Behandlung der obstruktiven hypertrophen Kardiomyopathie (oHCM; ). Der Antrag auf EU-Marktzulassung wird zurzeit von der Europ\u00e4ischen Arzneimittel-Agentur (EMA) gepr\u00fcft . Mit einem positiven Bescheid ist jedoch zu rechnen. Die hypertrophe Kardiomyopathie (HCM) umfasst eine heterogene, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im April 2022 erteilte die US-amerikanische Food and Drug Administration (FDA) die Marktzulassung f\u00fcr Mavacamten (Camzyos\u00ae; Bristol Myers Squibb) zur Behandlung der obstruktiven hypertrophen Kardiomyopathie (oHCM; ). Der Antrag auf EU-Marktzulassung wird zurzeit von der Europ\u00e4ischen Arzneimittel-Agentur (EMA) gepr\u00fcft . Mit einem positiven Bescheid ist jedoch zu rechnen. Die hypertrophe Kardiomyopathie (HCM) umfasst eine heterogene, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5693,5691,2905,5692,5690,5694],"class_list":["post-30812","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-explorer-hcm-studie","tag-hypertrophe-obstruktive-kardiomyopathie","tag-kardiomyopathie","tag-mavacamten","tag-obstruktive-hypertrophe-kardiomyopathie","tag-valor-hcm-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/30812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=30812"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/30812\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=30812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=30812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=30812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}